Serum apelin as a potential biomarker for infantile hemangiomas
Pediatric Blood & Cancer · 2024
DOI: 10.1002/pbc.30989 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Qiang Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Min…. Hauptthemen laut MEDLINE: Apelin, Biomarkers, Tumor. Die Arbeit nennt 59 Literaturangaben. Gefördert von: Chongqing Postgraduate Scientific Research Innovation Project, National Children's Health and Disease Clinical Medical Research Center Youth Program of Clinical Medical Research.
Abstract (Originalsprache)
Background
Infantile hemangiomas (IHs) are common benign vascular tumors in infants. Apelin, an endogenous cytokine, is implicated in the angiogenesis of neoplastic diseases. We aimed to explore the association between apelin and IHs, providing a foundation for clinical applications.
Methods
We identified differential expression of apelin in proliferative IHs compared to healthy controls (HCs) through bioinformatics analysis of publicly available databases and verified by Immunofluorescence. Enzyme‐linked immunosorbent assay was used to quantify the serum levels of apelin and vascular endothelial growth factor (VEGF) in a cohort of 116 cases of proliferative IHs, 65 cases of capillary malformations (CMs), and 70 HCs.
Results
Apelin and APJ ( APLNR , apelin receptor) were identified as the significantly upregulated differentially expressed genes (DEGs) in proliferative IHs. Immunofluorescence staining indicated high expression of apelin in proliferative IHs, while minimal expression in non‐IH lesions. Apelin in IHs was reduced following 6 months of propranolol treatment. Serum apelin levels were significantly higher in the IH group compared to both the CM and HC groups. Moreover, apelin exhibited excellent discriminatory ability in distinguishing IHs from HCs, with an area under the curve (AUC) exceeding 0.90. A positive correlation was observed between the levels of apelin and the size of superficial IHs. The expression profiles of VEGF and apelin in IHs were found to be consistent.
Conclusions
Apelin shows promise as a potential biomarker for IHs. The association between apelin and IH size, as well as its responsiveness to propranolol treatment, indicates its possible utility as a valuable indicator for the therapeutic evaluation of IHs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders,…
- Department of Pediatric Surgery, Chongqing University Three Gorges Hospital, Chongqing, China.
- Pediatric Research Institute, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Coopera…
ORCID-Profile: Qiang Chen
Förderung
- Chongqing Postgraduate Scientific Research Innovation Project
- National Children's Health and Disease Clinical Medical Research Center Youth Program of Clinical Medical Research
Zitieren
APA
Chen, Q., Zhang, Y., Ni, S., Yang, L., Li, J., Yuan, X., Chen, M., Liu, J., Luo, X., Xie, Y., & Wang, H. (2024). Serum apelin as a potential biomarker for infantile hemangiomas. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30989
Vancouver
Chen Q, Zhang Y, Ni S, Yang L, Li J, Yuan X, et al. Serum apelin as a potential biomarker for infantile hemangiomas. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.30989
BibTeX
@article{Chen2024,
author = {Chen, Qiang and Zhang, Yunxuan and Ni, Sili and Yang, Liuqing and Li, Jiwei and Yuan, Xingang and Chen, Meng and Liu, Jing and Luo, Xiaoyan and Xie, Yimin and Wang, Hua},
title = {Serum apelin as a potential biomarker for infantile hemangiomas},
journal = {Pediatric Blood & Cancer},
year = {2024},
doi = {10.1002/pbc.30989}
}
EUVIMED